Polymorphism of MDM2 promoter 309 (rs 2279744) and the risk of PCOS

References

• King J. Polycystic ovary syndrome. J Midwife Women’s Health 2006;51:415–22
   PubMed Web of Science ®Google Scholar
• Jeffrey CR. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191:713–17
   PubMed Web of Science ®Google Scholar
• Futterweit W, Mechanick J. Polycystic ovarian disease: etiology, diagnosis, and treatment. Comprehens Therap 1988;14:12–20
   PubMedGoogle Scholar
• Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327–31
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Human Reprod 1997;12:2641
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan Y, Dai J, et al. Exacerbation of diabetes-induced testicular apoptosis by zinc deficiency is most likely associated with oxidative stress, p38 MAPK activation, and p53 activation in mice. Toxicol Lett 2011;200:100–6
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Naito K. Effects of 4-hydroxy-2-nonenal, a marker of oxidative stress, on spermatogenesis and expression of p53 protein in male infertility. J Urol 2007;178:1012–17
   PubMed Web of Science ®Google Scholar
• Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM21 1 NIH (CA74172 and CA70712). Mol Canc Res 2003;1:1009–16
   PubMed Web of Science ®Google Scholar
• Peng Q, Mo C, Qin A, et al. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis. J Exp Clin Cancer Res 2013;32:85
   PubMed Web of Science ®Google Scholar
• Dockerty MB, Jackson RL. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957;73:161–73
   PubMed Web of Science ®Google Scholar
• Polat M, Boynukalin FK, Yarali I, et al. Endometriosis is not associated with inferior pregnancy rates in in vitro fertilization: an analysis of 616 patients. Gynecol Obstet Invest 2014;78:59–64
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005;11:631–43
   PubMed Web of Science ®Google Scholar
• Lenarcik A, Bidzinska-Speichert B, Tworowska-Bardzinska U, Krepula K. Hormonal abnormalities in first-degree relatives of women with polycystic ovary syndrome (PCOS). Endokrynol Pol 2011;62:129–33
   PubMed Web of Science ®Google Scholar
• Rajender S, Carlus SJ, Bansal SK, et al. Androgen receptor CAG repeats length polymorphism and the risk of polycystic ovarian syndrome (PCOS). PLoS One 2013;8:e75709
   PubMed Web of Science ®Google Scholar
• Reddy KR, Deepika ML, Supriya K, et al. CYP11A1 microsatellite (tttta)n polymorphism in PCOS women from South India. J Assist Reprod Genet 2014;31:857–63
   PubMed Web of Science ®Google Scholar
• Carr-Wilkinson J, Griffiths R, Elston R, et al. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle 2011;10:3778–87
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002;12:53–9
   PubMed Web of Science ®Google Scholar
• Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007;28:2262–7
   PubMed Web of Science ®Google Scholar
• Li G, Zhai X, Zhang Z, et al. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006;27:2028–33
   PubMed Web of Science ®Google Scholar
• Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591–602
   PubMed Web of Science ®Google Scholar
• Wang LH, Wang X, Xu WT, Hu YL. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol 2014;35:3167–70
   PubMed Web of Science ®Google Scholar
• Paulin FE, O'Neill M, McGregor G, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 2008;8:281
   PubMed Web of Science ®Google Scholar